Original writing on multi-specific design, cryptographic provenance, the honest quantum question, and what we’re learning building NOVA-3 in the open. New posts weekly.
What bispecifics, trispecifics, and VHH shuttles actually are, why pharma keeps reaching for them, and why they are hard to build.
Screening treats antibody discovery as a search problem; we treat it as a composition problem, and that change reorganizes everything downstream.